All In Biotech

Drug Trial Radar · NCT07016412

Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)

A Phase IIb, Randomized, Double-blind, Placebo- Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ensifentrine-glycopyrrolate Fixed-dose Combination at Two Dose Levels Compared to Glycopyrrolate or Ensifentrine Monotherapy in Subjects With COPD

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 497 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

497

Actual

Start

Jul 31, 2025

Primary completion

Aug 17, 2026

Study completion Aug 17, 2026

Sponsor

Sponsor type
Industry
First posted
Jun 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult participants with chronic obstructive pulmonary disease (COPD).

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Ensifentrine 3 mgDrug

    Administered by a standard jet nebulizer, twice daily for 28 consecutive days

  • Glycopyrrolate 21.25 mcgDrug

    Administered by a standard jet nebulizer, twice daily for 28 consecutive days

  • Glycopyrrolate 42.5 mcgDrug

    Administered by a standard jet nebulizer, twice daily for 28 consecutive days

  • PlaceboDrug

    Administered by a standard jet nebulizer, twice daily for 28 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Average Forced Expiry Volume in 1 Second (FEV1) Area Under the Curve Versus Time From Time 0 to 4 Hours (AUC0-4h)Time frame: Baseline and Day 28

Locations

57 sites in 1 country. Site status is shown where the registry gives one.

  • SEC Clinical Research, LLC

    Dothan, Alabama

  • Elite Clinical Studies, LLC

    Phoenix, Arizona

  • Tucson Clinical Research Institute

    Tucson, Arizona

  • Downtown LA Research Center Inc - ClinEdge

    Los Angeles, California

  • California Medical Research Associates, Inc.

    Northridge, California

  • Northern California Research Corp

    Sacramento, California

  • Clinical Research of West Florida Inc

    Clearwater, Florida

  • Fleming Island Center For Clinical Research

    Fleming Island, Florida

  • Florida Institute For Clinical Research LLC

    Orlando, Florida

  • Ormond Beach Clinical Research

    Ormond Beach, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • Clinical Research of West Florida Inc - Tampa

    Tampa, Florida

  • Centricity Research Columbus Georgia Multispecialty - PPDS

    Columbus, Georgia

  • ASHA Clinical Research - Hammond

    Hammond, Indiana

  • Velocity Clinical Research - Valparaiso

    Valparaiso, Indiana

  • Velocity Clinical Research (Rockville - Maryland) - PPDS

    Rockville, Maryland

  • Revive Research Institute, Inc

    Southfield, Michigan

  • Clinical Research Institute, Inc - CRN

    Plymouth, Minnesota

  • Midwest Chest Consultants PC

    Saint Charles, Missouri

  • Midwest Clinical Research LLC

    St Louis, Missouri

  • The Clinical Research Center LLC - CRN

    St Louis, Missouri

  • Sierra Clinical Research

    Las Vegas, Nevada

  • Trialfinity Clinical Research Center

    Hamilton, New Jersey

  • Horizon Family Medical Group - New Windsor Primary Care

    New Windsor, New York

  • American Health Research Inc

    Charlotte, North Carolina

  • Clinical Research of Gastonia

    Gastonia, North Carolina

  • Stern Research Partners, LLC

    Huntersville, North Carolina

  • Monroe Biomedical Research -343 Venus St

    Monroe, North Carolina

  • Carolina Research Center, Inc

    Shelby, North Carolina

  • Bernstein Clinical Research Center Inc

    Cincinnati, Ohio

  • Remington Davis Clinical Research

    Columbus, Ohio

  • Advance Clinical Research

    Kettering, Ohio

  • Clinical Research Associates of Central PA

    DuBois, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Velocity Clinical Research - Anderson - PPDS

    Anderson, South Carolina

  • Pharmacorp Clinical Trials Incorporated

    Charleston, South Carolina

  • Piedmont Research Partners LLC

    Fort Mill, South Carolina

  • Velocity Clinical Research - Gaffney - PPDS

    Gaffney, South Carolina

  • Lowcountry Lung and Critical Care PA

    North Charleston, South Carolina

  • Monroe Biomedical Research Charleston

    North Charleston, South Carolina

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.